Incidental prostate cancer in TURP specimens: is PSA reliable in patients under 60 years of age
38th European Congress of Pathology, Stockholm, İsveç, 12 - 16 Eylül 2026, cilt.489, sa.1, ss.159-160, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Cilt numarası: 489
- Basıldığı Şehir: Stockholm
- Basıldığı Ülke: İsveç
- Sayfa Sayıları: ss.159-160
- Manisa Celal Bayar Üniversitesi Adresli: Evet
Özet
Background & Objectives: Objective: Incidental prostate adenocarcinoma(iPCa) detected in transurethral resection of the prostate (TURP) specimens is well described in elderly patients; however, its clinical significance and relationship with prostate-specific antigen (PSA) in younger individuals remain unclear. This study aimed to evaluate tumour characteristics and the predictive value of PSA in patients under 60 years of age. Methods: Materials and Methods: In this retrospective study, a total of 1493 TURP specimens from a 10-year archive were reviewed. Prostate adenocarcinoma was identified in 224 cases (15%), which constituted the study cohort. Patients were divided into two groups: <60 and ≥60 years. PSA levels (PSA values were not available in a subset of consultation cases and were excluded from the analysis), Grade Group, Gleason score, tumour percentage, perineural invasion (PNI), and prior prostate cancer history were compared. Results: Results: Sixteen patients (7.1%) were <60 years, while 208(92.9%) were 60 years or older. Mean PSA levels were lower in the younger group (26.6 vs 48.3 ng/ mL). However, tumour burden (approximately 53% vs 52%), Gleason score (7.9 vs 8.2), and PNI rates (12.5% vs 10.5%) were comparable between groups. Notably, the rate of clinically significant disease (Grade Group ≥2) was nearly identical (87.5% vs 87.1%). A higher proportion of younger patients had a prior diagnosis of prostate cancer (50% vs 30.6%, p = 0.04). Notably, clinically significant tumours were identified despite low PSA levels in the younger cohort. Conclusion: Conclusion: Although less frequent, incidental prostate cancer in patients under 60 years of age demonstrates tumour burden and grade comparable to older patients. Despite lower PSA levels in this group, clinically significant disease remains highly prevalent. These findings suggest that PSA alone may be insufÏcient for risk stratification in younger patients undergoing TURP and should be interpreted with caution in this population.